Groundbreaking new research on the cancer-fighting potential of vitamin C has made the pages of the peer-reviewed journal Science Translational Medicine. A team of researchers from the University of Kansas reportedly tested the effects of vitamin C given in high doses intravenously on a group of human subjects and found that it effectively eradicates cancer cells while leaving healthy cells intact.
Building upon earlier research pioneered in the 1970s by the late Linus Pauling, a chemist from Oregon State University who today is recognized as the world’s foremost proponent of therapeutic vitamin C, the new research involved injecting high doses of vitamin C into human ovarian cells. The tests were conducted in vitro in a lab, as well as directly in both mice and a group of 22 human subjects.
According to BBC News, the tests showed favorable results in all three models, as the vitamin C effectively targeted the ovarian cancer cells while avoiding healthy cells. The benefits of high-dose vitamin C were also observed in conjunction with conventional chemotherapy treatments, which destroy all cells, both healthy and malignant, eventually leading to patient death.
“Patients are looking for safe and low-cost choices in their management of cancer,” stated Dr. Jeanne Drisko, a co-author of the study, to BBC News concerning the findings. “Intravenous vitamin C has that potential based on our basic science research and early clinical data.”
Researchers admit more human trials on intravenous vitamin C unlikely because drug companies cannot patent vitamins
The next step for this type of research would typically involve applying these same parameters in a large-scale clinical human trial to see if they can be replicated and confirmed. While this new study is admittedly convincing on its own, the hurdles to gaining widespread acceptance of its findings include replicating them across a much larger human sample size.
But this may never actually take place. And the reason, says the research team, is that such trials require major funding that typically comes from pharmaceutical companies interested in developing a patented drug. Drug companies, in other words, are hardly interesting in promoting the medicinal benefits of natural substances like vitamin C, which stands to decimate the multibillion-dollar conventional cancer industry if word gets out about its benefits.
“Because vitamin C has no patent potential, its development will not be supported by pharmaceutical companies,” says Qi Chen, lead author of the new study. “We believe that the time has arrived for research agencies to vigorously support thoughtful and meticulous clinical trials with intravenous vitamin C.”
The conventional medical industry’s response to these and similar findings over the years has been nothing short of derisive, which is to be expected. Having to rationalize decades of ushering cancer patients through the gauntlet of chemotherapy, radiation and surgery — with dismal results — while ignoring natural cancer-fighting alternatives like vitamin C is a hard pill to swallow for this powerful, high-profit industry, which would rather everyone ignore such findings than think critically about them.
“[A]scorbate is processed by the body in different ways when administered orally versus intravenously,” writes Heidi Ledford for Nature about this commonly misunderstood variance. The medical-industrial complex, it turns out, intentionally corrupts the conversation on vitamin C by convoluting the distinct effects of these very different delivery routes.
“Oral doses [of vitamin C] act as antioxidants, protecting cells from damage caused by reactive compounds that contain oxygen. But vitamin C given intravenously can have the opposite effect by promoting the formation of one of those compounds: hydrogen peroxide. Cancer cells are particularly susceptible to damage by such reactive oxygen-containing compounds.”